Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib, Sintilimab, and HAIC for Unresectable HCC
NCT05166772Phase 2
Key facts
- Status
- Unknown
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Modality
- Small Molecules
- Drugs
- donafenib
- Conditions
- hepatocellular carcinoma (HCC)
01
Overview
Phase 2, open-label trial of donafenib in hepatocellular carcinoma (HCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Registry description
The investigators design a phase IIB clinical study to explore the efficacy and safety of Donafenib combined with Sintilimab and HAIC in the first-line treatment of unresectable hepatocellular carcinoma
Beyond the preview
Go deeper on NCT05166772.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05166772.